Search

Your search keyword '"Hagemeister, Fredrick B."' showing total 712 results
Start Over Author "Hagemeister, Fredrick B."
712 results on '"Hagemeister, Fredrick B."'

1. Safety and activity of lenalidomide in combination with obinutuzumab in patients with relapsed indolent non-Hodgkin lymphoma: a single group, open-label, phase 1/2 trial

Author

Gurumurthi, Ashwath, Chin, Collin K., Feng, Lei, Fowler, Nathan H., Strati, Paolo, Hagemeister, Fredrick B., Fayad, Luis E., Westin, Jason R., Obi, Chizobam, Arafat, Janine, Nair, Ranjit, Steiner, Raphael E., Neelapu, Sattva S., Flowers, Christopher R., and Nastoupil, Loretta J.

Published
2024
Full Text
View/download PDF

3. Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma

Author

Janku, Filip, Park, Haeseong, Call, S Greg, Madwani, Kiran, Oki, Yasuhiro, Subbiah, Vivek, Hong, David S, Naing, Aung, Velez-Bravo, Vivianne M, Barnes, Tamara G, Hagemeister, Fredrick B, Falchook, Gerald S, Karp, Daniel D, Wheler, Jennifer J, Piha-Paul, Sarina A, Garrido-Laguna, Ignacio, Shpall, Elizabeth J, Fayad, Luis E, Neelapu, Sattva S, Meric-Bernstam, Funda, Kurzrock, Razelle, and Fanale, Michelle A

Subjects
Clinical Research, Clinical Trials and Supportive Activities, Lymphoma, Rare Diseases, Transplantation, Hematology, Cancer, Evaluation of treatments and therapeutic interventions, 6.2 Cellular and gene therapies, Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Brentuximab Vedotin, Dose-Response Relationship, Drug, Drug-Related Side Effects and Adverse Reactions, Everolimus, Female, Hematopoietic Stem Cell Transplantation, Histone Deacetylase Inhibitors, Histone Deacetylases, Hodgkin Disease, Humans, Male, Middle Aged, Recurrence, Sirolimus, Stem Cell Transplantation, TOR Serine-Threonine Kinases, Vorinostat, Young Adult, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposePreclinical and early clinical data suggested that combining histone deacetylase (HDAC) and mTOR inhibitors can synergistically inhibit Hodgkin lymphoma.Patients and methodsDuring the dose-escalation study (ClinicalTrials.gov number: NCT01087554) with the HDAC inhibitor vorinostat and the mTOR inhibitor sirolimus (V+S), a patient with Hodgkin lymphoma refractory to nine prior therapies demonstrated a partial response (PR) lasting for 18.5 months, which promoted additional enrollment of patients with Hodgkin lymphoma as well as exploration of an alternative combination of vorinostat and mTOR inhibitor everolimus (V+E).ResultsA total of 40 patients with refractory Hodgkin lymphoma received V+S (n = 22) or V+E (n = 18). Patients received a median of five prior therapies, including brentuximab (n = 39), autologous stem cell transplantation (n = 26), and allogeneic stem cell transplantation (n = 12). The most frequent grade ≥3 treatment-related adverse event was thrombocytopenia in 55% and 67% of patients treated with V+S and V+E, respectively. Complete response was reported in 6 (27%) patients treated with V+S and 2 (11%) patients treated with V+E, and PR was reported in 6 patients (27%) treated with V+S and 4 (22%) patients treated with V+E (objective response rate of 55% and 33%, respectively). In summary, combined HDAC and mTOR inhibition had encouraging activity in heavily pretreated patients with relapsed/refractory Hodgkin lymphoma and warrants further investigation.ConclusionsCombined HDAC and mTOR inhibition has salutary activity in patients with relapsed refractory Hodgkin lymphoma and warrants further investigation.

Published
2020

4. A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL

Author

Xu-Monette, Zijun Y, Zhang, Hongwei, Zhu, Feng, Tzankov, Alexandar, Bhagat, Govind, Visco, Carlo, Dybkaer, Karen, Chiu, April, Tam, Wayne, Zu, Youli, Hsi, Eric D, You, Hua, Huh, Jooryung, Ponzoni, Maurilio, Ferreri, Andrés JM, Møller, Michael B, Parsons, Benjamin M, van Krieken, J Han, Piris, Miguel A, Winter, Jane N, Hagemeister, Fredrick B, Shahbaba, Babak, De Dios, Ivan, Zhang, Hong, Li, Yong, Xu, Bing, Albitar, Maher, and Young, Ken H

Subjects
Orphan Drug, Human Genome, Hematology, Cancer, Rare Diseases, Lymphoma, Biotechnology, Genetics, Generic health relevance, Good Health and Well Being, Artificial Intelligence, B-Lymphocytes, Germinal Center, High-Throughput Nucleotide Sequencing, Humans, Lymphoma, Large B-Cell, Diffuse
Abstract

Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous entity of B-cell lymphoma. Cell-of-origin (COO) classification of DLBCL is required in routine practice by the World Health Organization classification for biological and therapeutic insights. Genetic subtypes uncovered recently are based on distinct genetic alterations in DLBCL, which are different from the COO subtypes defined by gene expression signatures of normal B cells retained in DLBCL. We hypothesize that classifiers incorporating both genome-wide gene-expression and pathogenetic variables can improve the therapeutic significance of DLBCL classification. To develop such refined classifiers, we performed targeted RNA sequencing (RNA-Seq) with a commercially available next-generation sequencing (NGS) platform in a large cohort of 418 DLBCLs. Genetic and transcriptional data obtained by RNA-Seq in a single run were explored by state-of-the-art artificial intelligence (AI) to develop a NGS-COO classifier for COO assignment and NGS survival models for clinical outcome prediction. The NGS-COO model built through applying AI in the training set was robust, showing high concordance with COO classification by either Affymetrix GeneChip microarray or the NanoString Lymph2Cx assay in 2 validation sets. Although the NGS-COO model was not trained for clinical outcome, the activated B-cell-like compared with the germinal-center B-cell-like subtype had significantly poorer survival. The NGS survival models stratified 30% high-risk patients in the validation set with poor survival as in the training set. These results demonstrate that targeted RNA-Seq coupled with AI deep learning techniques provides reproducible, efficient, and affordable assays for clinical application. The clinical grade assays and NGS models integrating both genetic and transcriptional factors developed in this study may eventually support precision medicine in DLBCL.

Published
2020

5. SIRPα+ macrophages are increased in patients with FL who progress or relapse after frontline lenalidomide and rituximab

Author

Marques-Piubelli, Mario L., Parra, Edwin R., Feng, Lei, Soto, Luisa Solis, Gallardo, Mariana, Gouni, Sushanth, Samaniego, Felipe, Noorani, Mansoor, Hagemeister, Fredrick B., Westin, Jason R., Lee, Hun Ju, Rodriguez, Maria A., Neelapu, Sattva S., Gunther, Jillian R., Fowler, Nathan H., Flowers, Christopher R., Wistuba, Ignacio I., Nastoupil, Loretta J., Vega, Francisco, and Strati, Paolo

Published
2022
Full Text
View/download PDF

6. Ibrutinib–rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial

Author

Wang, Michael L, Jain, Preetesh, Zhao, Shuangtao, Lee, Hun Ju, Nastoupil, Loretta, Fayad, Luis, Ok, Chi Young, Kanagal-Shamanna, Rashmi, Hill, Holly A, Yao, Yixin, Hagemeister, Fredrick B, Westin, Jason R, Fowler, Nathan, Samaniego, Felipe, Steiner, Raphael, Nair, Ranjit, Iyer, Swaminathan P, Navsaria, Lucy, Badillo, Maria, Feng, Lei, Xuelin, Huang, Nogueras Gonzalez, Graciela M, Xu, Guofan, Wagner-Bartak, Nicolaus, Thirumurthi, Selvi, Santos, David, Tang, Guilin, Lin, Pei, Wang, Sa A, Jorgensen, Jeff, Yin, C Cameron, Li, Shaoying, Patel, Keyur P, Vega, Francisco, Medeiros, L Jeffery, Flowers, Christopher R, and Wang, Linghua

Published
2022
Full Text
View/download PDF

8. Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma

Author

Strati, Paolo, Nastoupil, Loretta J., Westin, Jason, Fayad, Luis E., Ahmed, Sairah, Fowler, Nathan H., Hagemeister, Fredrick B., Lee, Hun J., Iyer, Swaminathan P., Nair, Ranjit, Parmar, Simrit, Rodriguez, Maria A., Samaniego, Felipe, Steiner, Raphael E., Wang, Michael, Pinnix, Chelsea C., Adkins, Sherry, Claussen, Catherine M., Martinez, Charles S., Hawkins, Misha C., Johnson, Nicole A., Singh, Prachee, Mistry, Haleigh E., Horowitz, Sandra, George, Shirley, Feng, Lei, Kebriaei, Partow, Shpall, Elizabeth J., Neelapu, Sattva S., Tummala, Sudhakar, and Chi, T. Linda

Published
2020
Full Text
View/download PDF

9. Can we cure refractory Hodgkin’s lymphoma with transplantation?

Author

Ciurea, Stefan O., Kongtim, Piyanuch, Srour, Samer, Saini, Neeraj, Im, Jin, Ramdial, Jeremy, Khouri, Issa, Anderlini, Paolo, Popat, Uday, Hosing, Chitra, Champlin, Richard E., Lee, Hun J., Fayad, Luis E., Hagemeister, Fredrick B., Bica, Ana M., Lipan, Lavinia, Craciun, Oana, Jercan, Cristina G., Tanase, Alina, and Colita, Anca

Published
2021
Full Text
View/download PDF

10. Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms

Author

Albitar, Maher, Zhang, Hong, Goy, Andre, Xu-Monette, Zijun Y., Bhagat, Govind, Visco, Carlo, Tzankov, Alexandar, Fang, Xiaosheng, Zhu, Feng, Dybkaer, Karen, Chiu, April, Tam, Wayne, Zu, Youli, Hsi, Eric D., Hagemeister, Fredrick B., Huh, Jooryung, Ponzoni, Maurilio, Ferreri, Andrés J. M., Møller, Michael B., Parsons, Benjamin M., van Krieken, J. Han, Piris, Miguel A., Winter, Jane N., Li, Yong, Xu, Bing, and Young, Ken H.

Published
2022
Full Text
View/download PDF

11. CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma

Author

Takahashi, Koichi, Sivina, Mariela, Hoellenriegel, Julia, Oki, Yasuhiro, Hagemeister, Fredrick B, Fayad, Luis, Romaguera, Jorge E, Fowler, Nathan, Fanale, Michelle A, Kwak, Larry W, Samaniego, Felipe, Neelapu, Sattva, Xiao, Lianchun, Huang, Xuelin, Kantarjian, Hagop, Keating, Michael J, Wierda, William, Fu, Kai, Chan, Wing C, Vose, Julie M, O'Brien, Susan, Davis, Richard E, and Burger, Jan A

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Cancer, Rare Diseases, Lymphoma, Hematology, Clinical Research, Aetiology, 2.1 Biological and endogenous factors, Adenine, Antineoplastic Agents, B-Cell Activation Factor Receptor, Biomarkers, Tumor, Cell Line, Tumor, Chemokine CCL3, Chemokine CCL4, Enzyme-Linked Immunosorbent Assay, Epidemiologic Methods, Humans, Lymphoma, Large B-Cell, Diffuse, Piperidines, Prognosis, Pyrazoles, Pyrimidines, Signal Transduction, chemokines, diffuse large B-cell lymphoma, lymphoma, Cardiorespiratory Medicine and Haematology, Immunology, Cardiovascular medicine and haematology
Abstract

B cell receptor (BCR) signalling is an important pathway in diffuse large B cell lymphoma (DLBCL). In response to BCR triggering, normal and malignant B cells secrete the chemokines CCL3 and CCL4 to attract accessory cells to the tissue microenvironment. We measured CCL3 and CCL4 serum concentrations in 102 patients with newly diagnosed DLBCL by enzyme-linked immunosorbent assay, investigated their prognostic impact and validated our findings in an independent cohort of 51 patient samples. We also tested CCL3 and CCL4 secretion by DLBCL cells, and the influence of BTK inhibitors on the secretion of these chemokines. High CCL3 (≥40 pg/ml) serum concentrations correlated with higher international prognostic index, lactate dehydrogenase and β2 microglobulin, as did CCL4 (≥180 pg/ml) with advanced Ann Arbor stages. High CCL3 levels correlated with significantly shorter progression-free and overall survival. The in vitro studies demonstrated that activated B cell-like, but not germinal centre B cell-like DLBCL cells, secrete high levels of CCL3 and CCL4 after BCR triggering, which was exquisitely sensitive to BCR pathway inhibition. These findings support CCL3 and CCL4 protein concentrations as biomarkers for BCR pathway activation and prognosis in DLBCL.

Published
2015

12. Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study

Author

Gordon, Max J., primary, Feng, Lei, additional, Strati, Paolo, additional, Lee, Hun Ju, additional, Hagemeister, Fredrick B., additional, Westin, Jason R., additional, Samaniego, Felipe, additional, Marques‐Piubelli, Mario L., additional, Vega Vazquez, Francisco, additional, Parra Cuentas, Edwin R., additional, Solis‐Soto, Luisa M., additional, Ma, Wencai, additional, Wang, Jing, additional, Claret, Linda, additional, Averill, Barbara, additional, Ibanez, Karina, additional, Fayad, Luis E., additional, Flowers, Christopher R., additional, Green, Michael R., additional, Davis, R. Eric, additional, Neelapu, Sattva S., additional, Fowler, Nathan H., additional, and Nastoupil, Loretta J., additional

Published
2023
Full Text
View/download PDF

14. Tumor-infiltrating normal B cells revealed by immunoglobulin repertoire clonotype analysis are highly prognostic and crucial for antitumor immune responses in DLBCL

Author

Xu-Monette, Zijun Y., primary, Li, Yong, additional, Snyder, Thomas, additional, Yu, Tiantian, additional, Lu, Tingxun, additional, Tzankov, Alexandar, additional, Visco, Carlo, additional, Bhagat, Govind, additional, Qian, Wenbin, additional, Dybkaer, Karen, additional, Chiu, April, additional, Tam, Wayne, additional, Zu, Youli, additional, Hsi, Eric D., additional, Hagemeister, Fredrick B., additional, Wang, Yingjun, additional, Go, Heounjeong, additional, Ponzoni, Maurilio, additional, Ferreri, Andrés J.M., additional, Moller, Michael B., additional, Parsons, Benjamin M., additional, Fan, Xiangshan, additional, van Krieken, J.Han, additional, Piris, Miguel A., additional, Winter, Jane N., additional, Au, Qingyan, additional, Kirsch, Ilan, additional, Zhang, Mingzhi, additional, Shaughnessy, John, additional, Xu, Bing, additional, and Young, Ken H., additional

Published
2023
Full Text
View/download PDF

16. Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study.

Author

Gordon, Max J., Feng, Lei, Strati, Paolo, Lee, Hun Ju, Hagemeister, Fredrick B., Westin, Jason R., Samaniego, Felipe, Marques‐Piubelli, Mario L., Vega Vazquez, Francisco, Parra Cuentas, Edwin R., Solis‐Soto, Luisa M., Ma, Wencai, Wang, Jing, Claret, Linda, Averill, Barbara, Ibanez, Karina, Fayad, Luis E., Flowers, Christopher R., Green, Michael R., and Davis, R. Eric

Subjects
MUCOSA-associated lymphoid tissue lymphoma, LENALIDOMIDE, BRUTON tyrosine kinase, RITUXIMAB, FOLLICULAR lymphoma
Abstract

Background: Follicular lymphoma (FL) and marginal zone lymphoma (MZL) are indolent non‐Hodgkin lymphomas (iNHL). Median survival for iNHL is approximately 20 years. Because standard treatments are not curative, patients often receive multiple lines of therapy with associated toxicity—rationally designed, combination therapies with curative potential are needed. The immunomodulatory drug lenalidomide was evaluated in combination with rituximab for the frontline treatment of FL in the phase 3 RELEVANCE study. Ibrutinib, an oral Bruton tyrosine kinase inhibitor, is active in NHL and was evaluated in combination with lenalidomide, rituximab, and ibrutinib (IRR) in a phase 1 study. Methods: The authors conducted an open‐label, phase 2 clinical trial of IRR for previously untreated FL and MZL. The primary end point was progression‐free survival (PFS) at 24 months. Results: This study included 48 participants with previously untreated FL grade 1–3a (N = 38), or MZL (N = 10). Participants received 12, 28‐day cycles of lenalidomide (15 mg, days 1–21 cycle 1; 20 mg, cycles 2–12), rituximab (375 mg/m2 weekly in cycle 1; day 1 cycles 2‐12), and ibrutinib 560 mg daily. With a median follow‐up of 65.3 months, the estimated PFS at 24 months was 78.8% (95% confidence interval [CI], 68.0%–91.4%) and 60‐month PFS was 59.7% (95% CI, 46.6%–76.4%). One death occurred unrelated to disease progression. Grade 3–4 adverse events were observed in 64.6%, including 50% with grade 3–4 rash. Conclusions: IRR is highly active as frontline therapy for FL and MZL. Compared to historical results with lenalidomide and rituximab, PFS is similar with higher grade 3–4 toxicity, particularly rash. The study was registered with ClinicalTrials.gov (NCT02532257). After 5 years of follow‐up from a phase 2 clinical trial of ibrutinib, lenalidomide, and rituximab in previously untreated patients with follicular and marginal zone lymphoma, the 5‐year progression‐free survival rate was 59.7% and the overall survival rate was 97.9%. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. Data from Follicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II Expression

Author

Han, Guangchun, primary, Deng, Qing, primary, Marques-Piubelli, Mario L., primary, Dai, Enyu, primary, Dang, Minghao, primary, Ma, Man Chun John, primary, Li, Xubin, primary, Yang, Haopeng, primary, Henderson, Jared, primary, Kudryashova, Olga, primary, Meerson, Mark, primary, Isaev, Sergey, primary, Kotlov, Nikita, primary, Nomie, Krystle J., primary, Bagaev, Alexander, primary, Parra, Edwin R., primary, Solis Soto, Luisa M., primary, Parmar, Simrit, primary, Hagemeister, Fredrick B., primary, Ahmed, Sairah, primary, Iyer, Swaminathan P., primary, Samaniego, Felipe, primary, Steiner, Raphael, primary, Fayad, Luis, primary, Lee, Hun, primary, Fowler, Nathan H., primary, Flowers, Christopher R., primary, Strati, Paolo, primary, Westin, Jason R., primary, Neelapu, Sattva S., primary, Nastoupil, Loretta J., primary, Vega, Francisco, primary, Wang, Linghua, primary, and Green, Michael R., primary

Published
2023
Full Text
View/download PDF

18. Supplementary Data from Follicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II Expression

Author

Han, Guangchun, primary, Deng, Qing, primary, Marques-Piubelli, Mario L., primary, Dai, Enyu, primary, Dang, Minghao, primary, Ma, Man Chun John, primary, Li, Xubin, primary, Yang, Haopeng, primary, Henderson, Jared, primary, Kudryashova, Olga, primary, Meerson, Mark, primary, Isaev, Sergey, primary, Kotlov, Nikita, primary, Nomie, Krystle J., primary, Bagaev, Alexander, primary, Parra, Edwin R., primary, Solis Soto, Luisa M., primary, Parmar, Simrit, primary, Hagemeister, Fredrick B., primary, Ahmed, Sairah, primary, Iyer, Swaminathan P., primary, Samaniego, Felipe, primary, Steiner, Raphael, primary, Fayad, Luis, primary, Lee, Hun, primary, Fowler, Nathan H., primary, Flowers, Christopher R., primary, Strati, Paolo, primary, Westin, Jason R., primary, Neelapu, Sattva S., primary, Nastoupil, Loretta J., primary, Vega, Francisco, primary, Wang, Linghua, primary, and Green, Michael R., primary

Published
2023
Full Text
View/download PDF

19. Supplementary Figure from Follicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II Expression

Author

Han, Guangchun, primary, Deng, Qing, primary, Marques-Piubelli, Mario L., primary, Dai, Enyu, primary, Dang, Minghao, primary, Ma, Man Chun John, primary, Li, Xubin, primary, Yang, Haopeng, primary, Henderson, Jared, primary, Kudryashova, Olga, primary, Meerson, Mark, primary, Isaev, Sergey, primary, Kotlov, Nikita, primary, Nomie, Krystle J., primary, Bagaev, Alexander, primary, Parra, Edwin R., primary, Solis Soto, Luisa M., primary, Parmar, Simrit, primary, Hagemeister, Fredrick B., primary, Ahmed, Sairah, primary, Iyer, Swaminathan P., primary, Samaniego, Felipe, primary, Steiner, Raphael, primary, Fayad, Luis, primary, Lee, Hun, primary, Fowler, Nathan H., primary, Flowers, Christopher R., primary, Strati, Paolo, primary, Westin, Jason R., primary, Neelapu, Sattva S., primary, Nastoupil, Loretta J., primary, Vega, Francisco, primary, Wang, Linghua, primary, and Green, Michael R., primary

Published
2023
Full Text
View/download PDF

20. EBV-positive DLBCL frequently harbors somatic mutations associated with clonal hematopoiesis of indeterminate potential

Author

Li, Yong, primary, Xu-Monette, Zijun Y., additional, Abramson, Jeremy, additional, Sohani, Aliyah R., additional, Bhagat, Govind, additional, Tzankov, Alexandar, additional, Visco, Carlo, additional, Zhang, Shanxiang, additional, Dybkaer, Karen, additional, Pan, Zenggang, additional, Xu, Min, additional, Tam, Wayne, additional, Zu, Youli, additional, Hsi, Eric D., additional, Hagemeister, Fredrick B., additional, Go, Heounjeong, additional, van Krieken, J. Han, additional, Winter, Jane N., additional, Ponzoni, Maurilio, additional, Ferreri, Andrés J. M., additional, Møller, Michael B., additional, Piris, Miguel A., additional, Wang, Yingjun, additional, Zhang, Mingzhi, additional, and Young, Ken H., additional

Published
2023
Full Text
View/download PDF

21. Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review

Author

Pinnix, Chelsea C., Shah, Jatin J., Chuang, Hubert, Costelloe, Colleen M., Medeiros, L. Jeffrey, Wogan, Christine F., Reed, Valerie, Smith, Grace L., Milgrom, Sarah, Patel, Krina, Huo, Jinhai, Turturro, Francesco, Romaguera, Jorge, Fayad, Luis, Oki, Yasuhiro, Fanale, Michelle A., Westin, Jason, Nastoupil, Loretta, Hagemeister, Fredrick B., Rodriguez, Alma, Qazilbash, Muzaffar, Shah, Nina, Bashir, Qaiser, Ahmed, Sairah, Nieto, Yago, Hosing, Chitra, Rohren, Eric, and Dabaja, Bouthaina

Published
2016
Full Text
View/download PDF

23. Supplementary Figure from Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma

Author

Xu-Monette, Zijun Y., primary, Wei, Li, primary, Fang, Xiaosheng, primary, Au, Qingyan, primary, Nunns, Harry, primary, Nagy, Máté, primary, Tzankov, Alexandar, primary, Zhu, Feng, primary, Visco, Carlo, primary, Bhagat, Govind, primary, Dybkaer, Karen, primary, Chiu, April, primary, Tam, Wayne, primary, Zu, Youli, primary, Hsi, Eric D., primary, Hagemeister, Fredrick B., primary, Sun, Xiaoping, primary, Han, Xin, primary, Go, Heounjeong, primary, Ponzoni, Maurilio, primary, Ferreri, Andrés J.M., primary, Møller, Michael B., primary, Parsons, Benjamin M., primary, van Krieken, J. Han, primary, Piris, Miguel A., primary, Winter, Jane N., primary, Li, Yong, primary, Xu, Bing, primary, Albitar, Maher, primary, You, Hua, primary, and Young, Ken H., primary

Published
2023
Full Text
View/download PDF

24. Supplementary File 2 from Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma

Author

Janku, Filip, primary, Park, Haeseong, primary, Call, S. Greg, primary, Madwani, Kiran, primary, Oki, Yasuhiro, primary, Subbiah, Vivek, primary, Hong, David S., primary, Naing, Aung, primary, Velez-Bravo, Vivianne M., primary, Barnes, Tamara G., primary, Hagemeister, Fredrick B., primary, Falchook, Gerald S., primary, Karp, Daniel D., primary, Wheler, Jennifer J., primary, Piha-Paul, Sarina A., primary, Garrido-Laguna, Ignacio, primary, Shpall, Elizabeth J., primary, Fayad, Luis E., primary, Neelapu, Sattva S., primary, Meric-Bernstam, Funda, primary, Kurzrock, Razelle, primary, and Fanale, Michelle A., primary

Published
2023
Full Text
View/download PDF

25. Supplementary Data from Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma

Author

Xu-Monette, Zijun Y., primary, Wei, Li, primary, Fang, Xiaosheng, primary, Au, Qingyan, primary, Nunns, Harry, primary, Nagy, Máté, primary, Tzankov, Alexandar, primary, Zhu, Feng, primary, Visco, Carlo, primary, Bhagat, Govind, primary, Dybkaer, Karen, primary, Chiu, April, primary, Tam, Wayne, primary, Zu, Youli, primary, Hsi, Eric D., primary, Hagemeister, Fredrick B., primary, Sun, Xiaoping, primary, Han, Xin, primary, Go, Heounjeong, primary, Ponzoni, Maurilio, primary, Ferreri, Andrés J.M., primary, Møller, Michael B., primary, Parsons, Benjamin M., primary, van Krieken, J. Han, primary, Piris, Miguel A., primary, Winter, Jane N., primary, Li, Yong, primary, Xu, Bing, primary, Albitar, Maher, primary, You, Hua, primary, and Young, Ken H., primary

Published
2023
Full Text
View/download PDF

26. Supplementary Figure 6 from Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma

Author

Janku, Filip, primary, Park, Haeseong, primary, Call, S. Greg, primary, Madwani, Kiran, primary, Oki, Yasuhiro, primary, Subbiah, Vivek, primary, Hong, David S., primary, Naing, Aung, primary, Velez-Bravo, Vivianne M., primary, Barnes, Tamara G., primary, Hagemeister, Fredrick B., primary, Falchook, Gerald S., primary, Karp, Daniel D., primary, Wheler, Jennifer J., primary, Piha-Paul, Sarina A., primary, Garrido-Laguna, Ignacio, primary, Shpall, Elizabeth J., primary, Fayad, Luis E., primary, Neelapu, Sattva S., primary, Meric-Bernstam, Funda, primary, Kurzrock, Razelle, primary, and Fanale, Michelle A., primary

Published
2023
Full Text
View/download PDF

27. Supplementary File 1 from Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma

Author

Janku, Filip, primary, Park, Haeseong, primary, Call, S. Greg, primary, Madwani, Kiran, primary, Oki, Yasuhiro, primary, Subbiah, Vivek, primary, Hong, David S., primary, Naing, Aung, primary, Velez-Bravo, Vivianne M., primary, Barnes, Tamara G., primary, Hagemeister, Fredrick B., primary, Falchook, Gerald S., primary, Karp, Daniel D., primary, Wheler, Jennifer J., primary, Piha-Paul, Sarina A., primary, Garrido-Laguna, Ignacio, primary, Shpall, Elizabeth J., primary, Fayad, Luis E., primary, Neelapu, Sattva S., primary, Meric-Bernstam, Funda, primary, Kurzrock, Razelle, primary, and Fanale, Michelle A., primary

Published
2023
Full Text
View/download PDF

28. Supplementary Figure 5 from Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma

Author

Janku, Filip, primary, Park, Haeseong, primary, Call, S. Greg, primary, Madwani, Kiran, primary, Oki, Yasuhiro, primary, Subbiah, Vivek, primary, Hong, David S., primary, Naing, Aung, primary, Velez-Bravo, Vivianne M., primary, Barnes, Tamara G., primary, Hagemeister, Fredrick B., primary, Falchook, Gerald S., primary, Karp, Daniel D., primary, Wheler, Jennifer J., primary, Piha-Paul, Sarina A., primary, Garrido-Laguna, Ignacio, primary, Shpall, Elizabeth J., primary, Fayad, Luis E., primary, Neelapu, Sattva S., primary, Meric-Bernstam, Funda, primary, Kurzrock, Razelle, primary, and Fanale, Michelle A., primary

Published
2023
Full Text
View/download PDF

29. Supplementary Table 1, Supplementary Table 2 from Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma

Author

Janku, Filip, primary, Park, Haeseong, primary, Call, S. Greg, primary, Madwani, Kiran, primary, Oki, Yasuhiro, primary, Subbiah, Vivek, primary, Hong, David S., primary, Naing, Aung, primary, Velez-Bravo, Vivianne M., primary, Barnes, Tamara G., primary, Hagemeister, Fredrick B., primary, Falchook, Gerald S., primary, Karp, Daniel D., primary, Wheler, Jennifer J., primary, Piha-Paul, Sarina A., primary, Garrido-Laguna, Ignacio, primary, Shpall, Elizabeth J., primary, Fayad, Luis E., primary, Neelapu, Sattva S., primary, Meric-Bernstam, Funda, primary, Kurzrock, Razelle, primary, and Fanale, Michelle A., primary

Published
2023
Full Text
View/download PDF

30. Predictors of Radiation Pneumonitis in Patients Receiving Intensity Modulated Radiation Therapy for Hodgkin and Non-Hodgkin Lymphoma

Author

Pinnix, Chelsea C., Smith, Grace L., Milgrom, Sarah, Osborne, Eleanor M., Reddy, Jay P., Akhtari, Mani, Reed, Valerie, Arzu, Isidora, Allen, Pamela K., Wogan, Christine F., Fanale, Michele A., Oki, Yasuhiro, Turturro, Francesco, Romaguera, Jorge, Fayad, Luis, Fowler, Nathan, Westin, Jason, Nastoupil, Loretta, Hagemeister, Fredrick B., Rodriguez, M. Alma, Ahmed, Sairah, Nieto, Yago, and Dabaja, Bouthaina

Published
2015
Full Text
View/download PDF

31. Pegylated Liposomal Doxorubicin Replacing Conventional Doxorubicin in Standard R-CHOP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma: An Open Label, Single Arm, Phase II Trial

Author

Oki, Yasuhiro, Ewer, Michael S., Lenihan, Daniel J., Fisch, Michael J., Hagemeister, Fredrick B., Fanale, Michelle, Romaguera, Jorge, Pro, Barbara, Fowler, Nathan, Younes, Anas, Astrow, Alan B., Huang, Xuelin, Kwak, Larry W., Samaniego, Felipe, McLaughlin, Peter, Neelapu, Sattva S., Wang, Michael, Fayad, Luis E., Durand, Jean-Bernard, and Alma Rodriguez, M.

Published
2015
Full Text
View/download PDF

32. Additional file 1 of PD-L1+ macrophages are associated with favorable features in primary mediastinal (thymic) large B-cell lymphoma

Author

Steiner, Raphael E., Parra, Edwin R., Vega, Francisco, Feng, Lei, Westin, Jason R., Neelapu, Sattva S., Strati, Paolo, Green, Michael R., Flowers, Christopher R., Solis, Luisa M., Wistuba, Ignacio I., Ahmed, Sairah, Nair, Ranjit, Hagemeister, Fredrick B., Noorani, Mansoor, and Marques-Piubelli, Mario L.

Abstract

Additional file 1: Methods; Figure S1. Representative pictures showing different cell densities of CD30+PD-L1+ cells. A-C) Multiplex immunofluorescence image of a case with low cell density of CD30+, PD-L1+, and CD30+PD-L1+ cells median: 20.46 cells/mm2, respectively. D-E) Multiplex immunofluorescence image of a case with high cell density of CD30+, PD-L1+, and CD30+PD-L1+ cells (median: 604.62 cells/mm2), respectively. Supplementary Table 1.

Published
2023
Full Text
View/download PDF

33. CD19 CAR-T Outcomes in Patients with EBV-Positive DLBCL

Author

Nair, Ranjit, primary, Ayers, Amy, additional, Nastoupil, Loretta J., additional, Gunther, Jillian R., additional, Fayad, Luis, additional, Fowler, Nathan H., additional, Miranda, Roberto N., additional, Hagemeister, Fredrick B., additional, Lee, Hun Ju, additional, Rodriguez, Maria Alma, additional, Steiner, Raphael, additional, Strati, Paolo, additional, Nieto, Yago, additional, Ramdial, Jeremy L., additional, Chihara, Dai, additional, Wang, Michael L., additional, Malpica Castillo, Luis E, additional, Saini, Neeraj, additional, Jain, Preetesh, additional, Pinnix, Chelsea C., additional, Dabaja, Bouthaina S., additional, Green, Michael R, additional, Flowers, Christopher R., additional, Medeiros, L. Jeffrey, additional, Marques-Piubelli, Mario L., additional, Vega, Francisco, additional, Noorani, Mansoor, additional, Ahmed, Sairah, additional, Westin, Jason, additional, Neelapu, Sattva S., additional, Feng, Lei, additional, and Iyer, Swaminathan Padmanabhan, additional

Published
2022
Full Text
View/download PDF

34. Targetable Cellular Etiology of Prolonged Cytopenia Following CD19 CAR T-Cell Therapy

Author

Li, Xubin, primary, Deng, Qing, additional, Henderson, Jared, additional, Watson, Grace, additional, Deaton, Laurel, additional, Cain, Taylor, additional, Fayad, Luis, additional, Iyer, Swaminathan Padmanabhan, additional, Hagemeister, Fredrick B., additional, Nastoupil, Loretta J., additional, Fowler, Nathan H., additional, Westin, Jason, additional, Steiner, Raphael, additional, Nair, Ranjit, additional, Ahmed, Sairah, additional, Alatrash, Gheath, additional, Neelapu, Sattva S., additional, Strati, Paolo, additional, and Green, Michael R, additional

Published
2022
Full Text
View/download PDF

35. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial

Author

Fowler, Nathan H, Davis, R Eric, Rawal, Seema, Nastoupil, Loretta, Hagemeister, Fredrick B, McLaughlin, Peter, Kwak, Larry W, Romaguera, Jorge E, Fanale, Michelle A, Fayad, Luis E, Westin, Jason R, Shah, Jatin, Orlowski, Robert Z, Wang, Michael, Turturro, Francesco, Oki, Yasuhiro, Claret, Linda C, Feng, Lei, Baladandayuthapani, Veerabhadran, Muzzafar, Tariq, Tsai, Kenneth Y, Samaniego, Felipe, and Neelapu, Sattva S

Published
2014
Full Text
View/download PDF

36. Positron Emission Tomography/Computed Tomography Findings During Therapy Predict Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Chemotherapy Alone but Not in Those Who Receive Consolidation Radiation

Author

Dabaja, Bouthaina S., Hess, Kenneth, Shihadeh, Ferial, Podoloff, Donald A., Medeiros, L. Jeffrey, Mawlawi, Osama, Arzu, Isidora, Oki, Yasuhiro, Hagemeister, Fredrick B., Fayad, Luis E., Reed, Valerie K., Kedir, Aziza, Wogan, Christine F., and Rodriguez, Alma

Published
2014
Full Text
View/download PDF

37. Zoledronic Acid for Prevention of Bone Loss in Patients Receiving Primary Therapy for Lymphomas: A Prospective, Randomized Controlled Phase III Trial

Author

Westin, Jason R., Thompson, Michael A., Cataldo, Vince D., Fayad, Luis E., Fowler, Nathan, Fanale, Michelle A., Neelapu, Saatva, Samaniego, Felipe, Romaguera, Jorge, Shah, Jatin, McLaughlin, Peter, Pro, Barbara, Kwak, Larry W., Sanjorjo, Perpetua, Murphy, William A., Jimenez, Camillo, Toth, Bela, Dong, Wenli, and Hagemeister, Fredrick B.

Published
2013
Full Text
View/download PDF

42. The survival outcome of patients with relapsed/refractory peripheral T‐cell lymphoma‐not otherwise specified and angioimmunoblastic T‐cell lymphoma

Author

Chihara, Dai, Fanale, Michelle A., Miranda, Roberto N., Noorani, Mansoor, Westin, Jason R., Nastoupil, Loretta J., Hagemeister, Fredrick B., Fayad, Luis E., Romaguera, Jorge E., Samaniego, Felipe, Turturro, Francesco, Lee, Hun J., Neelapu, Sattva S., Rodriguez, M. Alma, Wang, Michael, Fowler, Nathan H., Davis, Richard E., Medeiros, L. Jeffrey, Hosing, Chitra, Nieto, Yago L., and Oki, Yasuhiro

Published
2017
Full Text
View/download PDF

43. Follicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II Expression

Author

Han, Guangchun, primary, Deng, Qing, additional, Marques-Piubelli, Mario L., additional, Dai, Enyu, additional, Dang, Minghao, additional, Ma, Man Chun John, additional, Li, Xubin, additional, Yang, Haopeng, additional, Henderson, Jared, additional, Kudryashova, Olga, additional, Meerson, Mark, additional, Isaev, Sergey, additional, Kotlov, Nikita, additional, Nomie, Krystle J., additional, Bagaev, Alexander, additional, Parra, Edwin R., additional, Solis Soto, Luisa M., additional, Parmar, Simrit, additional, Hagemeister, Fredrick B., additional, Ahmed, Sairah, additional, Iyer, Swaminathan P., additional, Samaniego, Felipe, additional, Steiner, Raphael, additional, Fayad, Luis, additional, Lee, Hun, additional, Fowler, Nathan H., additional, Flowers, Christopher R., additional, Strati, Paolo, additional, Westin, Jason R., additional, Neelapu, Sattva S., additional, Nastoupil, Loretta J., additional, Vega, Francisco, additional, Wang, Linghua, additional, and Green, Michael R., additional

Published
2022
Full Text
View/download PDF

44. Brentuximab vedotin and nivolumab alone and then combined with rituximab, cyclophosphamide, doxorubicin, and prednisone for frontline therapy of patients with primary mediastinal large B-cell lymphoma.

Author

Steiner, Raphael Eric, primary, Strati, Paolo, additional, Flowers, Christopher, additional, Neelapu, Sattva Swarup, additional, Green, Michael Richard, additional, Nastoupil, Loretta J., additional, Hagemeister, Fredrick B., additional, Feng, Lei, additional, Ahmed, Sairah, additional, Nair, Ranjit, additional, Fayad, Luis, additional, Lee, Hun Ju, additional, Rodriguez, Maria Alma, additional, and Westin, Jason, additional

Published
2022
Full Text
View/download PDF

45. Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma

Author

Xu-Monette, Zijun Y., primary, Wei, Li, additional, Fang, Xiaosheng, additional, Au, Qingyan, additional, Nunns, Harry, additional, Nagy, Máté, additional, Tzankov, Alexandar, additional, Zhu, Feng, additional, Visco, Carlo, additional, Bhagat, Govind, additional, Dybkaer, Karen, additional, Chiu, April, additional, Tam, Wayne, additional, Zu, Youli, additional, Hsi, Eric D., additional, Hagemeister, Fredrick B., additional, Sun, Xiaoping, additional, Han, Xin, additional, Go, Heounjeong, additional, Ponzoni, Maurilio, additional, Ferreri, Andrés J.M., additional, Møller, Michael B., additional, Parsons, Benjamin M., additional, van Krieken, J. Han, additional, Piris, Miguel A., additional, Winter, Jane N., additional, Li, Yong, additional, Xu, Bing, additional, Albitar, Maher, additional, You, Hua, additional, and Young, Ken H., additional

Published
2022
Full Text
View/download PDF

46. Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma

Author

Jain, Preetesh, primary, Zhao, Shuangtao, additional, Lee, Hun Ju, additional, Hill, Holly A., additional, Ok, Chi Young, additional, Kanagal-Shamanna, Rashmi, additional, Hagemeister, Fredrick B., additional, Fowler, Nathan, additional, Fayad, Luis, additional, Yao, Yixin, additional, Liu, Yang, additional, Moghrabi, Omar B., additional, Navsaria, Lucy, additional, Feng, Lei, additional, Nogueras Gonzalez, Graciela M., additional, Xu, Guofan, additional, Thirumurthi, Selvi, additional, Santos, David, additional, Iliescu, Cezar, additional, Tang, Guilin, additional, Medeiros, L. Jeffrey, additional, Vega, Francisco, additional, Avellaneda, Michelle, additional, Badillo, Maria, additional, Flowers, Christopher R., additional, Wang, Linghua, additional, and Wang, Michael L., additional

Published
2022
Full Text
View/download PDF

47. Targetable Cellular Etiology of Prolonged Cytopenia Following CD19 CAR T-Cell Therapy

Author

Strati, Paolo, primary, Li, Xubin, additional, Deng, Qing, additional, Marques-Piubelli, Mario Luiz, additional, Henderson, Jared, additional, Balada, Grace, additional, Deaton, Laurel, additional, Cain, Taylor, additional, Yang, Haopeng, additional, Ravanmehr, Vida, additional, Fayad, Luis E., additional, Iyer, Swaminathan, additional, Nastoupil, Loretta J., additional, Hagemeister, Fredrick B., additional, Fowler, Nathan H., additional, Westin, Jason R., additional, Steiner, Raphael E., additional, Nair, Ranjit, additional, Flowers, Christopher R., additional, Wang, Linghua, additional, Ahmed, Sairah, additional, Al-Atrash, Gheath, additional, Vega, Francisco, additional, Neelapu, Sattva S., additional, and Green, Michael, additional

Published
2022
Full Text
View/download PDF

49. Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center

Author

Chihara, Dai, Cheah, Chan Y., Westin, Jason R., Fayad, Luis E., Rodriguez, Maria A., Hagemeister, Fredrick B., Pro, Barbara, McLaughlin, Peter, Younes, Anas, Samaniego, Felipe, Goy, Andre, Cabanillas, Fernando, Kantarjian, Hagop, Kwak, Larry W., Wang, Michael L., and Romaguera, Jorge E.

Published
2016
Full Text
View/download PDF

50. PD-L1+ macrophages are associated with favorable features in primary mediastinal (thymic) large B-cell lymphoma.

Author

Steiner, Raphael E., Parra, Edwin R., Vega, Francisco, Feng, Lei, Westin, Jason R., Neelapu, Sattva S., Strati, Paolo, Green, Michael R., Flowers, Christopher R., Solis, Luisa M., Wistuba, Ignacio I., Ahmed, Sairah, Nair, Ranjit, Hagemeister, Fredrick B., Noorani, Mansoor, and Marques-Piubelli, Mario L.

Subjects
MACROPHAGES, PROGNOSIS, THYMUS tumors, NON-Hodgkin's lymphoma, LYMPHOMAS, DISEASE relapse
Abstract

Primary mediastinal (thymic) large B-cell lymphoma (PMBCL) is a rare, aggressive subtype of non-Hodgkin lymphoma and has a complex inflammatory microenvironment. Although most patients can be cured with standard-of-care immunochemotherapy, patients who have disease relapse have an unfavorable prognosis. Pre-treatment prognostic biomarkers in PMBCL are needed. In this retrospective study, we analyzed the clinical features and outcomes of PMBCL patients and their association with immune cell subpopulations identified by multiplex immunofluorescence at initial diagnosis. Two different antibody panels were used to assess macrophages in tissue biopsy specimens collected before the initiation of induction therapy. Twelve PMBCL patients, including five patients who had disease relapse, were included in the analysis. At a median follow-up time of 32.2 months, the median progression-free and overall survival durations were not reached. Our findings suggest that a high density of PD-L1+ macrophages is associated with favorable features, such as early disease stage and the absence of B-symptoms, and indicate that a high percentage of PD-L1+ macrophages and high densities of CD30+PD-L1+ cells and CD30+ cells might be associated with a lower risk of relapse within 12 months of therapy initiation. Further studies are needed to develop a biomarker signature predictive of treatment response with therapeutic consequences for patients with newly diagnosed PMBCL. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results